Fibroblast growth factor-2-mediated protection of cardiomyocytes from the toxic effects of doxorubicin requires the mTOR/Nrf-2/HO-1 pathway - Koleini, N; Nickel, B E; Wang, J (Oncotarget, 2017)
et al.